Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind,Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

NCT02431468 is registered in ClinicalTrials.gov with Neurotrope Bioscience, Inc. as lead sponsor.

NCT NCT02431468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02431468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind,Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
Lead sponsor
Neurotrope Bioscience, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2015
Completion date
February 28, 2017
Enrollment
147 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease